HEINEKEN Teams Up With Blue Yonder To Improve Demand Planning
HEINEKEN, the world’s most international brewer, confirms Blue Yonder as a vendor of trust to further transform its supply chain planning capability. The global brewer will implement Blue Yonder Cognitive Demand Planning, a next generation cloud-native, microservices-based SaaS solution, that utilizes artificial intelligence (AI) and machine learning (ML) to improve forecast accuracy and reduce bias by considering dynamic external and internal variables.
HEINEKEN has been implementing Blue Yonder solutions for multiple years unlocking value for its business, especially with the potential to improve forecast accuracy through ML demand forecasting solution. HEINEKEN has selected Blue Yonder, as one of the current major supply chain solution providers, to future proof its demand planning process and leverage AI/ML, autonomous scenario planning, planning process orchestration and solution extensibility.
“We want to continuously improve our supply chain processes and adopting Blue Yonder Cognitive Demand Planning is an important step in that ambition. Working together with Blue Yonder will support us in our ambition to become the best-connected brewer and foster functional excellence in demand planning, leading to improved customer experience. And with the right supply response it could generate a positive impact on our sustainability targets as well, for example by reduced write-offs and less goods movements,” said Corneel Hindriks, manager, Digital & Technology - Global Planning, HEINEKEN.
Once the Blue Yonder Cognitive Demand Planning solution is implemented, HEINEKEN expects to achieve the following benefits:
- Make more informed, data-driven decisions: get all the real-world and business data HEINEKEN needs in a unified data cloud and integrate all planning processes to make better decisions – with speed and scale.
- Manage complexity and boost accuracy: combine the best output from statistical forecasting and extensible ML to deliver higher forecast accuracy and reduce bias.
- Respond faster: compress the planning cycle and empower planners to drive strategy and respond in the moment, not on a fixed schedule.
- Create and deploy customized and extended solutions: build, test and confidently deploy customized and extended ML models, workflows, personalized user experiences, and business logic at production scale with minimal effort.
Consumer goods companies are currently encountering challenges due to fluctuations in demand caused by inflation, supply chain disruptions, evolving consumer habits, and a growing demand for more sustainable products and processes. These industry dynamics pose a significant challenge for conventional forecasting methods. Blue Yonder Cognitive Demand Planning solution, which sits on Microsoft Azure, addresses these challenges with a new generation of AI-based capabilities, transforming the way companies around the world collaborate, predict, plan and make decisions.
“We are proud to bring our contribution as supply chain management leaders in supporting HEINEKEN’s mission to become the best-connected brewer. Blue Yonder’s future-proof solution helps a brewer like HEINEKEN to adapt to new external dynamics and changing market conditions, ensuring their supply chains remain agile, sustainable and competitive. Thanks to Blue Yonder Cognitive Demand Planning, HEINEKEN can optimize its supply chain and ensure that customers can always enjoy their preferred beers and beyond all over the world,” said Terry Turner, President, Manufacturing, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder Cognitive Demand Planning
- Video: Next Generation Demand Planning with Cognitive Demand Planning
About Heineken
HEINEKEN is the world's most international brewer. It is the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, the Group has a portfolio of more than 350 international, regional, local and specialty beers and ciders. With HEINEKEN’s over 90,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through "Brew a Better World", sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, maltings, cider plants and other production facilities in more than 70 countries. The most recent information is available on the Company's website and follow us on LinkedIn, Twitter and Instagram. For press inquiry please contact pressoffice@heineken.com.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515808653/en/
Contact information
Blue Yonder Public Relations:
Marina Renneke, APR, Global Corporate Communications Sr. Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com
Rossella Benti, EMEA Corporate Communications Director
Tel: +39 335 7849149, rossella.benti@blueyonder.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
